热疗联合TP方案化疗治疗中晚期非小细胞肺癌的临床观察  

Clinical Observation of Thermotherapy Combined with TP Chemotherapy in Treating Advanced Non-small Cell Lung Cancer

作　　者：陈维[1] 魏涛[1] 陈林[2] 

机构地区：[1]广州市花都区人民医院肿瘤科,广东广州510800 [2]广东工业大学轻工化工学院食品系,广东广州510006

出　　处：《中国医药指南》2014年第33期33-34,共2页Guide of China Medicine

摘　　要：目的探讨热疗联合TP方案化疗治疗中晚期非小细胞肺癌(NSCLC)的临床疗效、生活质量改善率和毒副反应。方法 40例入组的ⅢB期或Ⅳ期NSCLC患者,随机分为对照组(20例)和治疗组(20例),治疗组采用热疗联合TP方案化疗2周期,对照组仅行TP方案化疗2周期,比较两组间临床疗效、生活质量改善及毒副反应的差异。结果治疗组和对照组的有效率分别为65%和35%,差异有统计学意义(P<0.05);两组患者间生活质量改善率的差异有统计学意义(P<0.05);两组间毒副反应的差异无统计学意义(P>0.05)。结论热疗联合化疗治疗中晚期NSCLC疗效确切,生活质量明显改善,毒副反应可以耐受,值得临床推广应用。Objective To investigate the clinical efficacy, the change of KPS scores and side effects induced by therrnotherapy combined with TP chemotherapy in treating patients with advanced non-small cell lung cancer（NSCLC）. Methods Forty cases with NSCLC stage ⅢB or Ⅳ were enrolled in this study, they were randomly divided into two groups. The observation group （n=20） was treated with paclitaxel plus cisplatin （TP） for two cycles, combined with thermotherapy. The control group （n=20） was treated only with regular TP chemotherapy for two cycles. The clinical efficacy, the change of karnofsky （KPS） scores and side effects were compared between the two groups. Results The response rate in observation group was 65%, and 35% in control group. There was significant difference between two groups （P〈0.05）. The difference was significant in the change of KPS score before and after treatment between two groups （P〈0.05）. The toxic and side effects of the two groups had no significant difference （P〉0.05）. Conclusion Therrnotherapy combined with TP chemotherapy can increase efficacy and improve life quality of the patients with advanced NSCLC, and the toxicity can be tolerated, it was worthy for clinical use.

关 键 词：热疗 化疗 中晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]